Literature DB >> 739051

Myotonia dystrophica with heart involvement: an electron microscopic study of skeletal, cardiac, and smooth muscle.

R M Ludatscher, H Kerner, S Amikam, B Gellei.   

Abstract

The electron microscopic features of the striated skeletal muscle, the striated cardiac muscle, and the smooth muscle from a woman who had been suffering for many years from myotonia dystrophica with cardiac involvement are described. The skeletal muscle was studied at two different stages of the disease. In the first material the main changes consisted of centrally situated nuclei, disorganisation of the sarcomeres, and focal disruption of the Z-line. The satellite cells were well represented. Three years later atrophy and degenerative, necrotic changes of the skeletal muscle were evident. The satellite cells were absent. Few changes were seen in the striated cardiac muscle. These consisted of slight interstitial fibrosis and large accumulations of mitochondria with intramitochondrial dense granules. The smooth muscle cells of the oesophagus showed disorientated filaments and mild degenerative changes. It is concluded that the skeletal muscle was more severely affected than the other types of muscle.

Entities:  

Mesh:

Year:  1978        PMID: 739051      PMCID: PMC1145484          DOI: 10.1136/jcp.31.11.1057

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

1.  ULTRASTRUCTURE OF MUSCLE IN MYOTONIC DYSTROPHY: PRELIMINARY OBSERVATIONS.

Authors:  F P ALEU; A K AFIFI
Journal:  Am J Pathol       Date:  1964-08       Impact factor: 4.307

2.  AN ELECTRON MICROSCOPIC STUDY OF SKELETAL AND CARDIAC MUSCLE OF THE RAT POISONED BY PLASMOCID.

Authors:  A N D AGOSTINO
Journal:  Lab Invest       Date:  1963-11       Impact factor: 5.662

3.  ABNORMALITIES IN THE MUSCLE SPINDLES IN DYSTROPHIA MYOTONICA.

Authors:  P M DANIEL; S J STRICH
Journal:  Neurology       Date:  1964-04       Impact factor: 9.910

4.  ALCOHOLIC CARDIOMYOPATHY; AN ELECTRON MICROSCOPIC STUDY.

Authors:  R G HIBBS; V J FERRANS; W C BLACK; D G WEILBAECHER; G E BURCH
Journal:  Am Heart J       Date:  1965-06       Impact factor: 4.749

5.  SMOOTH MUSCLE INVOLVEMENT IN MYOTONIC DYSTROPHY.

Authors:  J C HARVEY; D H SHERBOURNE; C I SIEGEL
Journal:  Am J Med       Date:  1965-07       Impact factor: 4.965

6.  The heart and lungs in myotonic muscular dystrophy.

Authors:  P J CANNON
Journal:  Am J Med       Date:  1962-05       Impact factor: 4.965

7.  [Ultrastructural changes in striated muscle in myotonia dystrophica].

Authors:  R Ludatscher; S Amikam; B Gellei
Journal:  Harefuah       Date:  1976-06-01

8.  Electrophysiological and histological abnormalities of the heart in myotonic dystrophy.

Authors:  N Uemura; H Tanaka; T Niimura; N Hashiguchi; M Yoshimura; S Terashi; T Kanehisa
Journal:  Am Heart J       Date:  1973-11       Impact factor: 4.749

9.  Early ultrastructural and biochemical changes in muscle in dystrophia myotonica.

Authors:  I Mussini; S Di Mauro; C Angelini
Journal:  J Neurol Sci       Date:  1970-06       Impact factor: 3.181

10.  An ultrastructure investigation of intrafusal muscle fibers in myotonic dystrophy.

Authors:  J A Maynard; R R Cooper; V V Ionaescu
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1977-02-18
View more
  17 in total

Review 1.  Primary lipid cardiomyopathy.

Authors:  A Zimmermann; P Wyss; F Stocker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance.

Authors:  Saman Nazarian; David A Bluemke; Kathryn R Wagner; Menekhem M Zviman; Evrim Turkbey; Brian S Caffo; Monda Shehata; David Edwards; Barbara Butcher; Hugh Calkins; Ronald D Berger; Henry R Halperin; Gordon F Tomaselli
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

3.  Esophageal motor function in patients with myotonic dystrophy.

Authors:  M Costantini; G Zaninotto; M Anselmino; M Marcon; V Iurilli; C Boccù; G P Feltrin; C Angelini; E Ancona
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

4.  Muscleblind participates in RNA toxicity of expanded CAG and CUG repeats in Caenorhabditis elegans.

Authors:  Li-Chun Wang; Kuan-Yu Chen; Huichin Pan; Chia-Chieh Wu; Po-Hsuan Chen; Yuan-Ting Liao; Chin Li; Min-Lang Huang; Kuang-Ming Hsiao
Journal:  Cell Mol Life Sci       Date:  2010-09-17       Impact factor: 9.261

Review 5.  Gastrointestinal manifestations in myotonic muscular dystrophy.

Authors:  Massimo Bellini; Sonia Biagi; Cristina Stasi; Francesco Costa; Maria Gloria Mumolo; Angelo Ricchiuti; Santino Marchi
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

6.  Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.

Authors:  Misha Koshelev; Satyam Sarma; Roger E Price; Xander H T Wehrens; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2010-01-05       Impact factor: 6.150

7.  Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.

Authors:  Guey-Shin Wang; Debra L Kearney; Mariella De Biasi; George Taffet; Thomas A Cooper
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 8.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

9.  Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert.

Authors:  U Mielke; A Haass; S Sen; W Schmidt
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

10.  Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.

Authors:  Marielle Brockhoff; Nathalie Rion; Kathrin Chojnowska; Tatiana Wiktorowicz; Christopher Eickhorst; Beat Erne; Stephan Frank; Corrado Angelini; Denis Furling; Markus A Rüegg; Michael Sinnreich; Perrine Castets
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.